A biotech founder makes the most consequential legal decisions in the first eighteen months, often before revenue and sometimes before a full team exists. You incorporate, assign the founding IP, and close a first financing inside a window where one mistake compounds. Assign a patent to the wrong entity, and you lose freedom to operate. Sign a convertible note with off-market terms, and you give away equity you can't recover at Series A.
Counsel that fits a Series B company can bury a pre-seed founder in retainers and paralegal handoffs for work that a partner should do directly. Firm size and billing model decide fit as much as practice-area depth. A firm with the deepest FDA bench still hurts you if a first-year associate runs your cap table on the meter.
The ten firms below draw on Chambers, Best Lawyers, and LMG Life Sciences rankings plus demonstrated deal experience. Read each entry against your stage and budget, not just its reputation. The right choice depends on where you sit today, not where you hope to be in three years.
Most biotech founders at the pre-seed and seed stage don't need a firm with 800 attorneys and a Boston skyscraper. Zecca Ross Law Firm charges flat fees, so you know the cost of incorporation, your founder agreements, and your first financing before the work starts. A large firm bills you by the hour and hands early-stage work to junior associates and paralegals, which turns a routine cap table cleanup into a four-figure surprise. A fixed price removes that risk and lets you plan legal spend the same way you plan every other line item in a seed budget.
Hourly billing punishes the exact behavior early founders need, which is asking questions. Every call, every quick review, and every "can you look at this term sheet" adds to the meter, so founders stop asking and make expensive mistakes on their own. Zecca Ross prices the engagement up front, which means you can call your attorney about a licensing question without watching a clock. Founder-accessible pricing matters most in the window between incorporation and your first raise, when your legal needs are real but your bank account is not yet flush with venture money.
At Zecca Ross, a licensed attorney does your work and answers your questions directly. Large firms staff early-stage matters with the most junior people available and reserve partner attention for their marquee venture-backed clients. A pre-seed biotech founder rarely clears that bar, so you pay senior-partner overhead while receiving associate-level attention. Direct attorney access changes the calculation, because the person structuring your IP assignment agreements is the same person you email when a co-founder wants to leave.
Zecca Ross practices where a growing number of early-stage biotech companies actually incorporate and raise, which is Arizona and California. California remains the center of life sciences venture funding, and Arizona has built a real base of research-driven startups around its universities and health systems. A firm rooted in both states understands the investor networks, the state-specific formation questions, and the freedom-to-operate concerns a founder faces before a Series A. You get counsel that knows your market rather than a national firm treating your company as one file among thousands.
Zecca Ross covers the legal work that determines whether a biotech company survives its first two years. Entity formation, founder equity splits, IP assignment, licensing agreements, and the documents behind a pre-seed or seed round all fall inside the flat-fee engagement. The point is to get the foundation right before an acquirer or a Series A investor runs diligence, because errors made at formation are the most expensive ones to unwind later.
Best For: Pre-seed and seed-stage biotech and life sciences founders in Arizona and California who need predictable legal costs and direct access to the attorney doing the work.
Each firm below earns recognition from Chambers, Best Lawyers, and LMG Life Sciences, and each primarily serves Series A and later or venture-backed companies that already have legal infrastructure in place. Read each entry alongside its "Best For" callout to match a firm to your stage and needs.
Goodwin Procter closes more life sciences venture deals each year than nearly any other firm, which makes it the default choice for founders whose regulatory path is already complicated at incorporation. The firm built its reputation on volume, and that volume shows up in how quickly its teams move through emerging company formation, priced venture rounds, and the FDA questions that follow a therapeutic or diagnostic company from day one.
Goodwin pairs corporate work with a deep regulatory bench, so a founder raising a Series A can handle the financing and the licensing terms with the same firm. Its attorneys regularly structure the intellectual property licenses that anchor a biotech company's value, and they draft financing documents that institutional investors already recognize. That familiarity shortens negotiation because the venture funds across the table have seen Goodwin's paper before.
The firm operates from Boston and San Francisco, the two markets where most life sciences capital concentrates, and its founder clients tend to sit inside those investor networks. Goodwin's rates match its position at the top of the market, which means the model works best once a company has raised institutional money and can absorb large-firm billing.
Best For: VC-backed biotech startups raising a Series A or later with a complex FDA regulatory path and institutional investors who expect recognized counsel on both sides of the table.
Cooley LLP built its reputation on taking life sciences companies from a napkin sketch to a Nasdaq listing, and few firms match the depth of that pipeline. Rooted in Silicon Valley, Cooley has guided a large share of venture-backed biotech companies through the full arc of formation, financing rounds, and public offerings. That continuity matters because the lawyers who structured your seed round already understand your cap table when it comes time to price an IPO.
Cooley covers the transactional work an emerging biotech founder runs into at every stage. The firm handles entity formation and equity structuring, leads Series A through late-stage venture financings, and negotiates the IP licensing deals that often define a therapeutics company's value. On the exit side, Cooley advises on both public offerings and strategic acquisitions, and its corporate team works in tandem with capital markets specialists so a company preparing to go public isn't handing the file to strangers.
The firm operates from California with a national footprint, which gives founders access to both West Coast investor networks and the securities bench a Nasdaq listing demands. Cooley's rates reflect that positioning, so the fit is strongest once a company has raised institutional capital.
Best For: Life sciences startups targeting a Nasdaq IPO or preparing for a strategic acquisition, where continuity of counsel from formation through exit carries real weight.
WilmerHale pairs top-tier patent litigation with FDA regulatory work in a way most full-service firms cannot claim. Many large firms handle patent prosecution well, or run FDA regulatory practices well, but WilmerHale defends biotech patents in court and steers products through the approval process under one roof. For a founder whose entire valuation rests on a defensible patent estate, that combination removes the friction of coordinating two separate firms during a dispute.
The firm prosecutes and litigates patents, guides companies through FDA approval pathways, and represents clients in government investigations. WilmerHale also handles venture financing rounds, so a portfolio company can raise capital and defend its IP through the same relationship. Its government investigations practice matters most to biotech companies whose products draw scrutiny from federal agencies during trials or post-approval.
That regulatory and litigation depth comes at senior-firm rates, which fits companies with real IP exposure and less well with a founder filing a first provisional patent. WilmerHale earns its place when the patent portfolio is broad enough that a single infringement claim could sink the company, or when a regulatory decision carries existential weight.
Best For: biotech companies with complex IP portfolios or government regulatory exposure who need patent litigation and FDA counsel from the same firm.
Wilson Sonsini built its reputation representing Silicon Valley technology companies from formation through IPO, and it carries that same playbook into the growing field where biotech meets software. Founders working on digital health platforms, computational drug discovery, or diagnostics that lean heavily on data tend to fit its model well, because the firm treats the company like a tech startup that happens to operate in life sciences.
The core work covers entity formation, priced venture rounds, corporate governance, IP strategy, and M&A, with a clear California emphasis that reflects where most of its early-stage clients incorporate and raise. Wilson Sonsini attorneys know the West Coast venture funds by name and negotiate term sheets against those investors routinely, which shortens the learning curve on a first institutional round.
That California investor fluency also carries a cost. Rate structures assume a company that has already closed a seed round or expects to soon, so pre-seed founders often find the firm engages later than they need. If you are building a tech-enabled biotech company and plan to raise from California funds within a year, Wilson Sonsini gives you counsel that has seen your exact deal structure many times over.
Best For: Digital health and tech-enabled biotech startups with strong California investor networks and a near-term venture round.
Morrison Foerster earns its place through FDA regulatory depth that most full-service firms treat as a support function rather than a core practice. MoFo staffs former agency personnel and specialists who map approval pathways for drugs, biologics, and devices, which matters when a single regulatory misstep can delay a product by years.
The firm pairs that regulatory bench with transactional muscle, so a client working through a complex approval can also close licensing deals, financings, and M&A without switching counsel. That combination suits companies where deal activity and FDA strategy move on the same timeline, and where the two need to inform each other.
MoFo also runs a strong privacy and data practice that serves digital health companies handling patient information under HIPAA and state law. Its international offices extend that coverage to companies pursuing approvals or partnerships outside the United States, which becomes relevant once a therapeutic program reaches later stages.
Founders should weigh the rate structure. MoFo operates at top-tier billing, so the firm fits companies with financing in place and regulatory complexity that justifies the spend, not a pre-seed team filing its first provisional patent.
Best For: life sciences companies navigating complex FDA approval pathways while running active deal activity, where regulatory strategy and transactions need to stay coordinated under one firm.
Mintz runs a nationally recognized life sciences group that works with companies at every stage, from seed rounds through commercial-stage operations. The firm sits in the mid-large tier, which gives founders access to a deep bench without paying the rates that Goodwin or Cooley command in their Boston and San Francisco practices.
The life sciences team at Mintz covers the full range a biotech company needs as it grows. Its venture financing lawyers handle priced rounds and convertible instruments, and its intellectual property group prosecutes and defends patent portfolios that often define a startup's value. On the regulatory side, Mintz advises on FDA approval pathways, and its employment practice handles the founder equity and hiring questions that surface once a company starts scaling headcount. The firm maintains offices in Boston and California, which keeps it close to the two largest biotech investor communities.
Mintz appeals to founders who want a recognized name attached to their cap table and diligence file, but who balk at the top-tier billing structure that comes with the largest firms. You get lawyers who have worked across the biotech lifecycle at a rate that fits a Series A or Series B budget better than a marquee Boston firm would.
Best For: Emerging biotech companies that want recognized life sciences counsel without the largest-firm rate structure.
Gunderson Dettmer represents only companies and their founders, never venture capital firms, which sets it apart from every other firm on this list. That single choice removes a conflict most founders never think about until it costs them. When your firm also represents the fund writing your term sheet, the incentives split. Gunderson closed that door by design, so the lawyer negotiating your financing answers to you and no one on the other side of the table.
The firm built its entire practice around the startup lifecycle. It handles company formation, venture financing rounds, equity compensation plans, and eventual M&A or acquisition, which covers most of what a venture-backed biotech company needs from incorporation through exit. Founders who have raised through multiple rounds tend to know Gunderson by name because it structures financings on the company side across thousands of deals a year.
The tradeoff is stage. Gunderson works best once you have institutional backing or a priced round in motion, not at the pre-seed moment when you are still deciding whether to incorporate in Delaware. Its strength is negotiating against sophisticated investors, and you get the most value from that when there are sophisticated investors to negotiate against.
Best For: venture-backed biotech founders who want a firm that exclusively represents startups, not their investors.
Fenwick & West built its reputation by treating intellectual property and corporate work as one integrated practice, which fits biotech companies whose value lives in a technology platform rather than a single product. Its patent lawyers prosecute and litigate the filings that define freedom to operate, and its corporate team structures the venture rounds and licensing deals that turn that IP into revenue. Founders working with Fenwick get patent counsel and deal counsel who share the same file, so IP strategy shapes financing terms instead of arriving as an afterthought.
The firm operates from a California base with national reach, and it serves companies where a broad patent portfolio underpins multiple downstream applications. Fenwick's practice spans venture financing, corporate governance, and tax planning alongside IP prosecution and litigation, which matters when a platform company licenses the same core technology to several partners. For a biotech founder whose asset is a discovery engine or a delivery system rather than one molecule, that combination keeps legal work coordinated as the business scales.
Best For: platform biotech and life sciences companies where IP strategy sits at the center of the business model and drives financing, licensing, and partnership decisions.
Ropes & Gray works the buy side of life sciences deals that most firms only advise on from the sell side. Its private equity and healthcare M&A practice represents the sponsors and funds acquiring biotech and pharma assets, which means the firm negotiates from a position of experience most founders will never see across a table. When a private equity backer takes a stake in your company, Ropes & Gray is often the firm sitting across from you.
That deal focus shapes the rest of the practice. The firm handles fund formation for the investors backing life sciences companies, structures the complex acquisitions that follow, and layers in FDA regulatory and compliance work when a target carries approval risk. A founder engaging Ropes & Gray typically does so because a sophisticated financial sponsor is already involved, or because a strategic exit is on the near horizon and the deal will run into serious dollar figures.
The trade-off is straightforward. Ropes & Gray brings genuine transactional firepower to a late-stage or PE-backed company, but its rate structure and client mix make little sense for a founder still writing a first patent application or closing a seed round.
Best For: life sciences companies backed by private equity or preparing for a strategic exit.
Duane Morris runs a wide geographic network that reaches into markets the top-tier Boston and San Francisco firms rarely staff. The firm keeps offices across the country, including Southwest cities like Phoenix, which puts full-service life sciences counsel within reach of founders building outside the traditional biotech hubs. That footprint matters when you want a firm that understands local court systems and state regulatory quirks, not just federal FDA process.
The life sciences group at Duane Morris covers the range an operating biotech company needs. Its attorneys handle patent prosecution and IP portfolio work, FDA regulatory questions on product approval and labeling, transactional matters like licensing and financing, and litigation when a dispute reaches court. A company that wants one firm for both its patent strategy and its next product-liability defense can find both under one roof.
Duane Morris bills below the rates you would pay at Goodwin Procter or Cooley for comparable work. Founders who need genuine full-service coverage but cannot justify top-tier hourly rates get a practical middle option. The tradeoff is less concentrated venture-financing volume than the Silicon Valley specialists, so weigh that against the rate savings.
Best For: Life sciences companies in emerging biotech markets who need full-service counsel across IP, regulatory, and litigation at more accessible billing rates.
Three ranking sources anchored this list. Chambers USA, Best Lawyers, and LMG Life Sciences all evaluate firms on the depth of their life sciences work, and we cross-checked those rankings against demonstrated deal volume in venture financings, licensing, and FDA-regulated company formation. We then weighed practice breadth that actually matters to a founder, meaning IP, corporate, regulatory, and financing under one roof.
Read these rankings for what they measure. They reward large-firm ecosystems built to serve venture-backed companies with existing legal budgets and in-house teams. A pre-seed or seed-stage founder faces a different calculation. Billing model and direct attorney access often determine fit more than a firm's reputation does, which is why we included Zecca Ross Law Firm as the flat-fee alternative built for founders who need lawyer-led counsel before they have that infrastructure.
When should a biotech startup hire a law firm? Bring on counsel before you incorporate, not after. The choice of entity, founder equity split, and IP assignment agreements you sign in the first weeks shape every financing that follows. Fixing a botched cap table or an unassigned patent later costs far more than getting it right the first time.
What does a biotech lawyer actually do? A biotech lawyer handles the legal work that turns your science into a financeable company. That includes forming the entity, drafting founder and employee equity agreements, securing IP assignments, negotiating licenses, and papering your seed and venture rounds. A good one also flags FDA and regulatory questions early, so you know which pathways affect your fundraising timeline.
Do I need a Big Law firm or will a boutique work? At pre-seed and seed stage, a boutique usually serves you better. Large firms staff junior associates and paralegals on early-stage work while billing partner-level rates, and their attention follows their biggest clients. A boutique like Zecca Ross gives founders in Arizona and California direct attorney access without that overhead.
What's a flat-fee legal model and is it right for a startup? A flat-fee model charges a fixed price for a defined scope of work instead of billing by the hour. For a startup counting runway, predictable pricing means you can budget legal costs the way you budget everything else. It works well for the formation, equity, and financing work early biotech founders need most, which is exactly how Zecca Ross structures its engagements.
If you are raising a pre-seed or seed round in Arizona or California, a large firm will bill you by the hour and hand much of your work to a paralegal. Zecca Ross Law Firm gives you a flat fee you agree to upfront and a licensed attorney who does the work and answers your questions directly. You get founder-first counsel that fits the budget of a company still proving its science, not one preparing for a Nasdaq listing.
Book a consultation with Zecca Ross Law Firm today, and lock in predictable legal costs before your first financing closes.
Legal clarity starts here. Partner with Zecca Ross Law Firm to transform complexity into opportunity.